查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609560

基於體學的臨床試驗市場規模、佔有率和趨勢分析報告：2025-2030 年按階段、研究設計、適應症、地區和細分市場進行的預測

Omics-based Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Study Design (Interventional Studies, Observational Studies), By Indication, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

基於體學的臨床試驗市場成長與趨勢

Grand View Research, Inc. 的最新報告顯示，到 2030 年，全球基於體學的臨床試驗市場規模預計將達到 517.7 億美元。

預計2025年至2030年該市場將以8.02%的複合年成長率擴張。體學已被證明是分子研究的前沿方法。體學包括生物科學的所有領域。不同的部分被歸類為體學，包括蛋白質組學、基因組學、轉錄組學和代謝體學。冠狀病毒的爆發加速了臨床試驗中新方法、模型和技術的採用，這對市場成長產生了積極影響。

COVID-19 的爆發造成了嚴重破壞，幾乎擾亂了每個行業。最初，COVID-19 的爆發對臨床試驗生態系統產生了負面影響，影響了許多正在進行的針對多種適應症的試驗。然而，在 2020 年底，研究人員開始開發 COVID-19 的創新療法和疫苗，支持市場復甦和成長以及 CRO業務永續營運。癌症領域的臨床試驗活動不斷增加，癌症領域的臨床試驗達到歷史最高水準。了解 COVID-19 感染的廣泛研究將注意力集中在基於體學研究的應用上。

例如，2021 年 6 月，圖賓根大學醫院的一組研究人員啟動了一項臨床試驗，利用多組體學方法對不同候選 COVID-19 疫苗的遺傳和免疫反應進行比較分析。空間體學在生物標記識別中的日益成長的應用是推動市場成長的關鍵因素。為了研究藥物功效和毒性，空間組體學發揮重要作用，簡化了藥物發現和開發。生物標記鑑定廣泛應用於藥物開發和藥物發現以及臨床應用。生物標記用於識別疾病途徑、進展並闡明原因。

心臟疾病等慢性病盛行率不斷上升，以及新興市場對基於體學的臨床試驗的需求不斷成長，正在推動市場成長。癌症是美國的主要原因之一。光是 2018 年，估計就有 1,735,350 例新診斷和 609,640 例癌症相關死亡。單細胞多組學分析是一種新工具，為癌症治療開發打開了大門，並推進了當前的治療選擇。該市場也受到生技藥品的成長、對先進技術的需求以及對個人化藥物和孤兒藥的需求的推動。此外，生物技術和製藥行業的成長正在推動對非侵入性設備、單細胞多組體學技術的完整應用以及傳統實驗室的需求，從而推動未來市場的成長。

基於體學的臨床試驗市場報告亮點

  • III期細分市場佔據主導地位，2024年佔總收益佔有率的54.5%。根據臨床試驗統計數據，市場成長是由三期試驗的增加所推動的，三期試驗通常涉及更多的市場參與企業。
  • 2024 年，由於人們越來越重視個人化醫療，透過體學技術對個別病患資料進行客製化干預，干預研究領域佔據了市場主導地位。
  • 由於全球癌症發病率不斷上升以及對更有效治療策略的需求不斷成長，癌症細分市場將在 2024 年佔據市場主導地位。
  • 北美組體學臨床試驗市場在全球產業中佔據主導地位，2024年市佔率將達到38.0%。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章以體學為基礎的臨床試驗市場變數、趨勢、範圍

  • 市場體系展望
    • 母市場展望
    • 相關/補充市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 市場分析工具
    • 波特五力分析
    • PESTEL分析
    • COVID-19 影響分析

第4章基於體學的臨床試驗市場：階段、估計和趨勢分析

  • 細分儀表板
  • 全球體學臨床試驗市場，相變分析
  • 2018-2030 年基於體學的臨床試驗規模和趨勢（按階段）的全球分析
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章 以體學的臨床試驗市場：研究設計、估計與趨勢分析

  • 細分儀表板
  • 全球組體學臨床試驗市場、試驗設計變異分析
  • 2018-2030 年按研究設計分類的基於體學的臨床試驗規模和趨勢的全球分析
  • 干預研究
  • 觀察性研究
  • 擴大訪問研究

第6章以體學的臨床試驗市場：適應症、估計與趨勢分析

  • 細分儀表板
  • 全球組體學臨床試驗市場、適應症變異分析
  • 2018-2030 年基於體學的臨床試驗規模和適應症趨勢的全球分析
  • 自體免疫/炎症
  • 疼痛管理
  • 癌症
  • 中樞神經系統狀況
  • 糖尿病
  • 肥胖
  • 心血管
  • 其他

第7章基於體學的臨床試驗市場：區域、估計和趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司分類
  • 2024 年企業市場分析
  • 公司簡介
    • Parexel International（MA）Corporation
    • Thermo Fisher Scientific Inc.
    • Charles River Laboratories
    • ICON plc
    • SGS Societe Generale de Surveillance SA
    • Eli Lilly and Company
    • Pfizer Inc.
    • Laboratory Corporation of America
    • Novo Nordisk A/S
    • Rebus Biosystems, Inc.
Product Code: GVR-4-68039-905-9

Omics-Based Clinical Trials Market Growth & Trends:

The global omics-based clinical trials market size is anticipated to reach USD 51.77 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 8.02% from 2025 to 2030. Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The outbreak of COVID-19 has caused havoc and has disrupted almost every sector of industry. Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications. However, in the second half of 2020, researchers started developing innovative therapeutics and vaccines against COVID-19, which has supported the market recovery and growth, and continuance of business by CROs. There has been an increase in the clinical trials activity with oncology trials attaining historically high levels. The extensive research for understanding the COVID-19 infection has turned the attention to the application of omics-based studies.

For instance, in June 2021, a group of researchers at University Hospital Tuebingen initiated a clinical trial on comparative genetic and immune response analysis of different COVID-19 vaccine candidates using a multi-omics approach. The growing application of spatial OMICS, for the identification of biomarkers, is a major factor boosting the growth of the market. To study the efficacy and toxicity of the drug, spatial OMICS play a major role and have simplified drug discovery and development. Biomarker identification along with the clinical application is widely used in drug development and discovery. Biomarkers are used to identify the pathway of the diseases and the progression and help to understand the cause.

The rising prevalence of chronic diseases such as cancer and cardiac disorders and the increasing demand for omics-based clinical trials in developing countries are boosting the market's growth. Cancer is one of the leading causes of death in the United States. In 2018 alone, there were an estimated 1,735,350 new diagnoses and 609,640 cancer-related deaths. Single-cell multi-OMIC analysis is a novel tool that is opening doors in cancer drug development and further advance the current treatment options. The market is also driven by a rising number of biologics, demand for advanced technologies, and the need for personalized medicines and orphan drugs. Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering future market growth.

Omics-Based Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market, accounting for 54.5% of the total revenue share in 2024. Clinical trial statistics indicate that market growth is driven by an increase in phase III trials, which typically involve a large number of participants.
  • The interventional studies segment dominated the market in 2024 owing to its growing emphasis on personalized medicine by facilitating tailored interventions based on individual patient profiles derived from omics technologies.
  • The oncology segment dominated the market in 2024 owing to increasing prevalence of cancer globally coupled with growing need for more effective treatment strategies.
  • North America omics-based clinical trials market dominated the global industry and accounted for a 38.0% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Omics-Based Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Investment by Major Pharmaceutical Companies
      • 3.2.1.2. Shift Towards Personalized Medicine
      • 3.2.1.3. Growing Prevalence of Chronic Disorders
      • 3.2.1.4. Increasing Partnership and Collaboration
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Rising Costs of Clinical Trials
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Omics-Based Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Omics-Based Clinical Trials Market; Phase Movement Analysis
  • 4.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Omics-Based Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Omics-Based Clinical Trials Market; Study Design Movement Analysis
  • 5.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
  • 5.4. Interventional Studies
    • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Observational Studies
    • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Expanded Access Studies
    • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Omics-Based Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Omics-Based Clinical Trials Market; Indication Movement Analysis
  • 6.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 6.4. Autoimmune/inflammation
    • 6.4.1. Autoimmune/inflammation market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Pain management
    • 6.5.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Oncology
    • 6.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. CNS conditions
    • 6.7.1. CNS conditions market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Diabetes
    • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Obesity
    • 6.9.1. Obesity market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. Cardiovascular
    • 6.10.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. Others
    • 6.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Omics-Based Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. North America
    • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Competitive scenario
      • 7.3.2.3. Regulatory framework
      • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Competitive scenario
      • 7.3.3.3. Regulatory framework
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key country dynamics
      • 7.3.4.2. Competitive scenario
      • 7.3.4.3. Regulatory framework
      • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.4.2. UK
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Germany
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. France
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Italy
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Competitive scenario
      • 7.4.5.3. Regulatory framework
      • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Spain
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Competitive scenario
      • 7.4.6.3. Regulatory framework
      • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Denmark
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Competitive scenario
      • 7.4.7.3. Regulatory framework
      • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Sweden
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Competitive scenario
      • 7.4.8.3. Regulatory framework
      • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.9. Norway
      • 7.4.9.1. Key country dynamics
      • 7.4.9.2. Competitive scenario
      • 7.4.9.3. Regulatory framework
      • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Japan
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. China
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. India
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Australia
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. South Korea
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Thailand
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Brazil
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. Argentina
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 7.7.2. South Africa
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. Saudi Arabia
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. UAE
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. Kuwait
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Company Market Position Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. Parexel International (MA) Corporation
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Thermo Fisher Scientific Inc.
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Charles River Laboratories
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. ICON plc
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. SGS Societe Generale de Surveillance SA
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Eli Lilly and Company
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Pfizer Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Laboratory Corporation of America
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Novo Nordisk A/S
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Rebus Biosystems, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Service benchmarking
      • 8.3.10.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 4 Global Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 5 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 6 Global Omics-Based Clinical Trials Market, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Omics-Based Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 9 North America Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 10 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 12 U.S. Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 13 U.S. Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 14 Canada Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 15 Canada Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Canada Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 17 Mexico Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 18 Mexico Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Mexico Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 20 UK Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 21 UK Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 22 UK Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 23 Germany Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 24 Germany Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 25 Germany Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 26 France Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 27 France Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 28 France Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 29 Italy Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 30 Italy Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 31 Italy Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 32 Spain Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 33 Spain Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 34 Spain Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 35 Sweden Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 36 Sweden Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 37 Sweden Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 38 Norway Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 39 Norway Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 40 Norway Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 41 Denmark Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 42 Denmark Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 43 Denmark Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 44 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 45 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 46 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 47 China Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 48 China Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 49 China Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 50 Japan Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 51 Japan Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 52 Japan Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 53 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 54 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 55 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 56 Australia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 57 Australia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 58 Australia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 59 Thailand Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 60 Thailand Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 61 Thailand Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 62 South Korea Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 63 South Korea Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 64 South Korea Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 65 Brazil Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 66 Brazil Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 67 Brazil Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 68 Argentina Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 69 Argentina Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 70 Argentina Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 71 Saudi Arabia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 72 Saudi Arabia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 73 Saudi Arabia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 74 UAE Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 75 UAE Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 76 UAE Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
  • Table 77 Kuwait Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 78 Kuwait Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 79 Kuwait Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information Procurement
  • Fig. 2 Primary Research Pattern
  • Fig. 3 Market Research Approaches
  • Fig. 4 Value Chain-Based Sizing & Forecasting
  • Fig. 5 Market Formulation & Validation
  • Fig. 6 Omics-Based Clinical Trials Market, Market Segmentation
  • Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 9 Porter's Five Forces Analysis
  • Fig. 10 PESTEL Analysis
  • Fig. 11 Regional Marketplace: Key Takeaways
  • Fig. 12 Global Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 13 Global Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 14 Global Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 15 Global Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 16 Global Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 17 Global Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 18 Global Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 19 Global Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 20 Global Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 21 Global Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 22 Global Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 23 Global Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 24 Global Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 25 Global Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 26 Global Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 27 North America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 28 North America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 29 North America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 30 North America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 31 North America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 32 North America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 33 North America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 34 North America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 35 North America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 36 North America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 37 North America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 38 North America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 39 North America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 40 North America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 41 North America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 43 U.S. Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 46 U.S. Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 49 U.S. Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 50 U.S. Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 51 U.S. Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 53 U.S. Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 54 U.S. Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 55 U.S. Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 56 U.S. Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 57 Canada Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 58 Canada Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 59 Canada Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 60 Canada Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 61 Canada Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 62 Canada Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 63 Canada Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 64 Canada Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 65 Canada Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 66 Canada Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 67 Canada Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 68 Canada Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 69 Canada Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 70 Canada Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 71 Canada Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 72 Mexico Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 73 Mexico Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 74 Mexico Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 75 Mexico Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 76 Mexico Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 77 Mexico Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 78 Mexico Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 80 Mexico Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 81 Mexico Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 82 Mexico Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 83 Mexico Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 84 Mexico Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 85 Mexico Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 86 Mexico Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 87 Europe Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 88 Europe Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 89 Europe Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 90 Europe Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 91 Europe Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 92 Europe Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 93 Europe Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 94 Europe Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 95 Europe Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 96 Europe Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 97 Europe Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 98 Europe Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 99 Europe Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 100 Europe Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 101 Europe Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 102 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 103 UK Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 104 UK Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 105 UK Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 106 UK Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 107 UK Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 108 UK Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 109 UK Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 110 UK Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 111 UK Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 112 UK Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 113 UK Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 114 UK Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 115 UK Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 116 UK Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 117 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 118 Germany Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 119 Germany Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 120 Germany Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 121 Germany Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 122 Germany Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 123 Germany Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 124 Germany Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 125 Germany Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 126 Germany Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 127 Germany Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 128 Germany Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 129 Germany Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 130 Germany Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 131 Germany Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 132 France Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 133 France Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 134 France Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 135 France Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 136 France Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 137 France Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 138 France Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 139 France Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 140 France Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 141 France Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 142 France Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 143 France Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 144 France Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 145 France Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 146 France Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 147 Italy Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 148 Italy Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 149 Italy Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 150 Italy Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 151 Italy Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 152 Italy Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 153 Italy Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 154 Italy Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 155 Italy Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 156 Italy Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 157 Italy Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 158 Italy Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 159 Italy Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 160 Italy Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 161 Italy Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 162 Spain Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 163 Spain Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 164 Spain Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 165 Spain Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 166 Spain Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 167 Spain Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 168 Spain Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 169 Spain Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 170 Spain Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 171 Spain Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 172 Spain Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 173 Spain Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 174 Spain Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 175 Spain Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 176 Spain Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 177 Denmark Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 178 Denmark Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 179 Denmark Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 180 Denmark Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 181 Denmark Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 182 Denmark Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 183 Denmark Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 184 Denmark Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 185 Denmark Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 186 Denmark Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 187 Denmark Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 188 Denmark Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 189 Denmark Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 190 Denmark Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 191 Denmark Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 192 Sweden Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 193 Sweden Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 194 Sweden Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 195 Sweden Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 196 Sweden Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 197 Sweden Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 198 Sweden Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 199 Sweden Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 200 Sweden Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 201 Sweden Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 202 Sweden Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 203 Sweden Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 204 Sweden Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 205 Sweden Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 206 Sweden Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 207 Norway Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 208 Norway Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 209 Norway Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 210 Norway Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 211 Norway Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 212 Norway Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 213 Norway Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 214 Norway Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 215 Norway Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 216 Norway Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 217 Norway Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 218 Norway Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 219 Norway Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 220 Norway Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 221 Norway Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 222 Asia Pacific Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 223 Asia Pacific Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 224 Asia Pacific Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 225 Asia Pacific Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 226 Asia Pacific Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 227 Asia Pacific Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 228 Asia Pacific Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 229 Asia Pacific Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 230 Asia Pacific Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 231 Asia Pacific Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 232 Asia Pacific Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 233 Asia Pacific Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 234 Asia Pacific Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 235 Asia Pacific Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 236 Asia Pacific Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 237 China Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 238 China Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 239 China Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 240 China Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 241 China Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 242 China Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 243 China Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 244 China Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 245 China Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 246 China Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 247 China Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 248 China Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 249 China Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 250 China Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 251 China Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 252 Japan Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 253 Japan Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 254 Japan Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 255 Japan Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 256 Japan Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 257 Japan Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 258 Japan Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 259 Japan Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 260 Japan Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 261 Japan Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 262 Japan Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 263 Japan Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 264 Japan Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 265 Japan Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 266 Japan Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 267 India Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 268 India Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 269 India Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 270 India Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 271 India Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 272 India Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 273 India Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 274 India Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 275 India Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 276 India Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 277 India Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 278 India Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 279 India Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 280 India Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 281 India Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 282 Australia Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 283 Australia Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 284 Australia Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 285 Australia Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 286 Australia Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 287 Australia Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 288 Australia Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 289 Australia Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 290 Australia Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 291 Australia Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 292 Australia Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 293 Australia Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 294 Australia Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 295 Australia Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 296 Australia Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 297 Thailand Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 298 Thailand Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 299 Thailand Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 300 Thailand Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 301 Thailand Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 302 Thailand Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 303 Thailand Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 304 Thailand Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 305 Thailand Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 306 Thailand Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 307 Thailand Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 308 Thailand Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 309 Thailand Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 310 Thailand Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 311 Thailand Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 312 South Korea Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 313 South Korea Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 314 South Korea Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 315 South Korea Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 316 South Korea Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 317 South Korea Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 318 South Korea Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 319 South Korea Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 320 South Korea Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 321 South Korea Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 322 South Korea Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 323 South Korea Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 324 South Korea Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 325 South Korea Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 326 South Korea Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
  • Fig. 327 Latin America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
  • Fig. 328 Latin America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
  • Fig. 329 Latin America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
  • Fig. 330 Latin America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
  • Fig. 331 Latin America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
  • Fig. 332 Latin America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
  • Fig. 333 Latin America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
  • Fig. 334 Latin America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
  • Fig. 335 Latin America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
  • Fig. 336 Latin America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
  • Fig. 337 Latin America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
  • Fig. 338 Latin America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
  • Fig. 339 Latin America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
  • Fig. 340 Latin America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
  • Fig. 341 Latin America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)